| HHV-8 Serocon/T (%)N = 17/203 | COR (95%C.I.) | AOR (95%C.I.) | P |
---|---|---|---|---|
Gender | Â | Â | Â | Â |
Females | 2/36 (5.5) | 1.0 | 1.0 | Â |
Males | 15/167 (9.0) | 1.68 (0.36–15.77) | 1.46 (0.31–6.87) | .630 |
Age **(years) | Â | Â | Â | Â |
< 25 | 3/25 (12.0) | 1.0 | 1.0 | Â |
25–35 | 6/87 (6.9) | 0.54 (0.13–2.35) | 0.52 (0.11–2.37) | .402 |
> 35 | 8/91 (8.8) | 0.71 (0.17–2.90) | 0.56 (0.13–2.50) | .451 |
STI during follow-up | Â | Â | Â | Â |
None | 13/165 (7.9) | 1.0 | 1.0 | Â |
Any STI | 4/38 (10.5) | 1.38 (0.31–4.82) | 1.56 (0.38–5.96) | .586 |
   Other STI ^ | 3/31 (9.4) | 1.25 (0.22–4.98) | 1.36 (0.35–5.32) | .657 |
   Syphilis | 0/6 (-) | N.A. | - | - |
   Gonorrhea | 1/1 (100.0) | Undetermined | - | - |
HIV-1 during follow-up | Â | Â | Â | Â |
Non-seroconverted | 17/198 (8.6) | 1.0 | - | - |
Seroconverted | 0/5 (0.0) | N.A. | - | - |
No. sexual partners during follow-up | Â | Â | Â | Â |
< 3 | 2/55 (3.6) | 1.0 | 1.0 | Â |
3–5 | 6/74 (8.1) | 2.34 (0.45–12.05) | 2.45 (0.47–12.7) | .288 |
6–10 | 6/55 (10.9) | 3.24 (0.62–16.84) | 3.30 (0.62–17.4) | .160 |
> 10 | 3/19 (15.8) | 4.96 (0.76–32.35) | 3.46 (0.42–28.2) | .247 |